EPIX Stock Overview
A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
ESSA Pharma Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.20 |
52 Week High | US$11.67 |
52 Week Low | US$2.58 |
Beta | 1.76 |
1 Month Change | -15.07% |
3 Month Change | -37.75% |
1 Year Change | 108.75% |
3 Year Change | -81.00% |
5 Year Change | 210.00% |
Change since IPO | -92.98% |
Recent News & Updates
Recent updates
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate
Feb 18ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans
Aug 16Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)
Jan 25We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely
Dec 15ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen
Feb 02ESSA Pharma and Janssen to test combo treatments in prostate cancer setting
Jan 13ESSA Pharma EPS beats by $0.02
Dec 15Shareholder Returns
EPIX | US Biotechs | US Market | |
---|---|---|---|
7D | -8.0% | 2.4% | 2.3% |
1Y | 108.8% | 6.4% | 26.8% |
Return vs Industry: EPIX exceeded the US Biotechs industry which returned 5.4% over the past year.
Return vs Market: EPIX exceeded the US Market which returned 27.2% over the past year.
Price Volatility
EPIX volatility | |
---|---|
EPIX Average Weekly Movement | 7.9% |
Biotechs Industry Average Movement | 11.2% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EPIX's share price has been volatile over the past 3 months.
Volatility Over Time: EPIX's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 50 | David Parkinson | www.essapharma.com |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc. Fundamentals Summary
EPIX fundamental statistics | |
---|---|
Market cap | US$265.43m |
Earnings (TTM) | -US$25.80m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.6x
P/E RatioIs EPIX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EPIX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$25.80m |
Earnings | -US$25.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.58 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did EPIX perform over the long term?
See historical performance and comparison